Athira Pharma (NASDAQ:LONA) Upgraded at Wall Street Zen

Posted by Latisha Jones on Oct 19th, 2026

Wall Street Zen upgraded shares of Athira Pharma (NASDAQ:LONA – Free Report) to a hold rating in a research report released on Saturday,Wall Street Zen reports.

A number of other equities analysts have also recently issued reports on LONA. Mizuho cut their price objective on shares of Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 19th. Citizens Jmp reduced their target price on Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating for the company in a research note on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Athira Pharma has a consensus rating of “Moderate Buy” and an average price target of $17.33.

Check Out Our Latest Stock Report on LONA

Athira Pharma Stock Down 2.9%

Shares of NASDAQ LONA opened at $5.05 on Friday. The firm has a market cap of $47.42 million, a PE ratio of -1.20 and a beta of 2.11. Athira Pharma has a 12-month low of $2.21 and a 12-month high of $14.21. The company’s fifty day simple moving average is $6.55 and its 200 day simple moving average is $8.03.

Athira Pharma (NASDAQ:LONA – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.20). On average, equities analysts predict that Athira Pharma will post -2.67 earnings per share for the current year.

Athira Pharma Company Profile

(Get Free Report)

Athira Pharma, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for neurodegenerative diseases and other conditions involving impaired neuronal function. The company’s research has centered on the hepatocyte growth factor (HGF) biological pathway, which is associated with neuronal health, repair and regeneration.

Athira’s lead investigational product was fosgonimeton, also known as ATH-1017, an injectable therapy designed to activate the HGF/MET pathway.